Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
AssigneeEli Lilly and Company
InventorsRichard D. DiMarchi, Suad Efendic
Life of this patent
Estimating the term…
Abstract
This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
Claims20
A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising a glucagon-like peptide-1 (GLP-1), a glucagon-like peptide analog (GLP-1 analog), a glucagon-like peptide derivative (GLP-1 derivative) or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.
A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising Val8-GLP-1(7-37)OH having the amino acid sequence shown in SEQ ID NO:
- 6, or a pharmaceutically-acceptable salt thereof, in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.
A method of reducing body weight in a subject in need of body weight reduction by administering to the subject a composition comprising an agonist of glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.
A method of reducing body weight in a non-diabetic subject in need of body weight reduction by administering to the subject a composition comprising a glucagon-like peptide-1 (GLP-1), a glucagon-like peptide analog (GLP-1 analog), a glucagon-like peptide derivative (GLP-1 derivative) or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.
A method of reducing body weight in a non-diabetic subject in need of body weight reduction by administering to the subject a composition comprising Val8-GLP-1(7-37)OH having the amino acid sequence shown in SEQ ID NO:
- 6, or a pharmaceutically-acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.
A method of reducing body weight in a non-diabetic subject in need of body weight reduction by administering to the subject a composition comprising an agonist of glucagon-like peptide-1 receptor or a pharmaceutically acceptable salt thereof in a dose sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks.
Dependencies are inferred from the claim text.